Kirkland & Ellis is advising international investment firm BC Partners on the sale of Pharmathen, a leading European pharmaceutical company, to global private markets firm Partners Group (acting on behalf of its clients). The transaction values the business at c. €1.6 billion.
Pharmathen is the leading European drug delivery technology company. With a highly differentiated business model and strong management team, the company is a specialist in the development of “sustained release” technologies, with best-in-class R&D capabilities, serving a blue-chip customer base in nearly 100 countries worldwide. The transaction is subject to receipt of customary regulatory approvals and is expected to close in 2021.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
